BioNTech SE (BNTX) Key Metrics
BNTX key metrics, 2017–2025
Fiscal year ended December 31, 2025 · eurosBNTX returns How much profit the business earns on the capital it uses.
BNTX financial health Debt, liquidity and how easily interest is covered.
BNTX efficiency & capital use Working capital cycle and where the cash goes.
BNTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BNTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BNTX cash returned to shareholders
BNTX key metrics in euros
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | |||||||||
| Return on equity (ROE) | −5.7% | −3.4% | 4.6% | 59.1% | 155.2% | 1.6% | −47.2% | −44.3% | — |
| Return on invested capital (ROIC) | −13.1% | −30.5% | 10.7% | 112.8% | 201.3% | −41.5% | — | — | — |
| Return on assets (ROA) | −4.9% | −2.9% | 4.0% | 48.2% | 113.4% | 1.0% | −24.7% | −9.3% | −22.9% |
| Return on tangible assets | −5.5% | −3.1% | 4.3% | 40.9% | 65.9% | 0.7% | −25.3% | −8.5% | −29.4% |
| Free cash flow margin | 9.8% | −8.9% | 122.2% | 76.3% | 3.9% | −20.5% | −248.3% | −98.8% | −179.1% |
| Income quality (OCF / net income) | — | — | 5.77 | 1.44 | 0.09 | −0.89 | — | — | — |
| Financial health | |||||||||
| Total debt | €267.3M | €254.2M | €219.1M | €212.2M | €301.5M | €240.1M | €76.5M | €54.2M | €50.3M |
| Cash & short-term investments | €14.83B | €16.78B | €16.55B | €14.06B | €2.07B | €1.35B | €520.8M | €411.8M | €172.4M |
| Net debt | −€14.57B | −€16.53B | −€16.33B | −€13.85B | −€1.77B | −€1.11B | −€444.3M | −€357.6M | −€122.0M |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.18 | 0.16 | 0.20 | — |
| Debt / assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.10 | 0.10 | 0.08 | 0.13 |
| Net debt / EBITDA | — | — | −11.86 | −1.06 | −0.12 | — | — | — | — |
| Current ratio | 7.54 | 7.45 | 9.43 | 7.43 | 4.33 | 2.75 | 4.05 | 3.56 | 1.20 |
| Quick ratio | 7.49 | 7.34 | 9.26 | 7.28 | 4.18 | 2.64 | 3.97 | 3.51 | 1.17 |
| Interest coverage | -45.7 | -99.9 | 89.0 | 799.1 | — | -44.2 | -107.2 | -30.3 | -94.1 |
| Working capital | €14.00B | €16.28B | €17.46B | €18.97B | €11.59B | €1.06B | €422.0M | €322.8M | €31.1M |
| Invested capital | €4.65B | €2.88B | €3.92B | €6.20B | €10.12B | €264.5M | €49.2M | −€91.5M | −€171.3M |
| Tangible asset value | €17.24B | €18.24B | €19.08B | €19.84B | €11.69B | €1.21B | €404.1M | €179.0M | −€131.7M |
| Net current asset value | €13.38B | €15.68B | €16.77B | €18.70B | €11.14B | €720.1M | €256.0M | €63.0M | −€233.3M |
| Capital allocation | |||||||||
| Dividends paid | — | €0 | €0 | €484.3M | €0 | €0 | €0 | €0 | €0 |
| Share buybacks (net) | €0 | €0 | €738.5M | €986.4M | €0 | €0 | €0 | €0 | €0 |
| Dividend payout ratio | — | — | 0.0% | 5.1% | 0.0% | 0.0% | — | — | — |
| Dividends + buybacks / free cash flow | 0.0% | — | 15.8% | 11.1% | 0.0% | — | — | — | — |
| Capex / revenue | 6.1% | 16.4% | 18.5% | 2.1% | 0.8% | 17.7% | 65.5% | 53.2% | 93.7% |
| Capex / operating cash flow | 38.4% | 217.8% | 13.1% | 2.7% | 17.3% | — | — | — | — |
| Capex / depreciation | 0.46 | 1.52 | 3.85 | 2.95 | 2.05 | 2.21 | 2.10 | 3.09 | 5.48 |
| Stock-based compensation / revenue | 3.9% | 3.7% | 1.3% | 0.6% | 0.5% | 6.7% | 27.8% | 6.0% | 9.6% |
| R&D / revenue | 73.3% | 81.9% | 46.7% | 8.9% | 5.0% | 133.7% | 208.6% | 112.1% | 138.8% |
| SG&A / revenue | 25.3% | 21.8% | 14.6% | 2.8% | 1.5% | 19.8% | 39.9% | 21.2% | 47.9% |
| Efficiency | |||||||||
| Days sales outstanding | 166.1 | 256.3 | 453.3 | 205.9 | 120.7 | 70.3 | 81.7 | 47.2 | 27.1 |
| Days of inventory on hand | 116.6 | 216.1 | 242.6 | 57.4 | 35.5 | 233.3 | 183.7 | 128.8 | 151.8 |
| Days payables outstanding | 284.6 | 263.2 | 169.8 | 22.2 | 16.4 | 377.9 | 652.6 | 1,256.6 | 2,058.0 |
| Cash conversion cycle (days) | -1.9 | 209.2 | 526.1 | 241.1 | 139.7 | -74.3 | -387.2 | -1,080.5 | -1,879.1 |
| Receivables turnover | 2.20 | 1.42 | 0.81 | 1.77 | 3.02 | 5.19 | 4.47 | 7.73 | 13.46 |
| Payables turnover | 1.28 | 1.39 | 2.15 | 16.45 | 22.20 | 0.97 | 0.56 | 0.29 | 0.18 |
| Inventory turnover | 3.13 | 1.69 | 1.50 | 6.36 | 10.28 | 1.56 | 1.99 | 2.83 | 2.40 |
| Asset turnover | 0.12 | 0.12 | 0.17 | 0.89 | 2.09 | 0.31 | 0.15 | 0.25 | 0.16 |
| Average receivables | €1.25B | €1.93B | €4.74B | €9.76B | €6.27B | €92.9M | €24.3M | €16.5M | €4.6M |
| Average payables | €480.7M | €390.4M | €279.1M | €182.1M | €131.2M | €61.4M | €31.1M | €47.1M | €52.5M |
| Average inventory | €197.0M | €320.5M | €398.6M | €471.1M | €283.3M | €37.9M | €8.8M | €4.8M | €3.9M |
| Intangibles / total assets | 9.0% | 5.2% | 5.1% | 0.9% | 1.3% | 6.8% | 11.2% | 13.5% | 22.3% |
Computed from BNTX's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
BNTX valuation and financial ratios
BioNTech earned a return on equity of −5.7% and a return on invested capital of −13.1% in fiscal 2025. It ended the year with €267.3 million of debt and €14.8 billion in cash and short-term investments, a net cash position of €14.6 billion.
See the BNTX income statement, the BNTX chart for price history, or the BNTX stock overview for the latest quote and news.
BNTX key metrics FAQ
What is BioNTech's return on equity?
BioNTech's return on equity (ROE) was −5.7% in fiscal 2025: net income of -€1.1 billion on average shareholders' equity of €19.3 billion.
What is BioNTech's ROIC?
BioNTech's return on invested capital was −13.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BioNTech have?
BioNTech had total debt of €267.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is BioNTech's current ratio?
BioNTech's current ratio was 7.54 at the end of fiscal 2025: current assets were 7.54 times current liabilities.